滤泡性淋巴瘤（FL）是西方国家继弥漫性大 B 细胞淋巴瘤之后第二常见的非霍奇金淋巴瘤。大多数 FL 患者没有症状。随着时间的推移，生存率一直在上升，这主要是由于先进的治疗策略一名 51 岁男性，有糖尿病控制良好的病史，接受胰岛素治疗，因右腹股沟淋巴结肿大恶化超过 3 个月而到血液肿瘤科诊所就诊。他没有出现长时间发烧、盗汗或体重减轻的症状。初步体检显示，一名健康男性患有右侧腹股沟淋巴结肿大。然后将患者转诊给外科医生，并对肿大的右侧腹股沟淋巴结进行切除活检。因此，建立了 II 期大块症状低度 FL。我们每 3 周进行一次利妥昔单抗和苯达莫司汀化学免疫治疗，共六个周期。患者对治疗耐受良好，完成了6个周期的化学免疫治疗，后续FDG PET/CT显示疾病完全缓解。经过苯达莫司汀-利妥昔单抗系列化学免疫治疗后，患者达到完全缓解。该患者仍需要进一步评估，以确保淋巴瘤的缓解状态。

Follicular lymphoma (FL) is the second most common non-Hodgkin lymphoma in Western countries after diffuse large B-cell lymphoma. Most patients with FL present with asymptomatic disease. Survival rates have been rising over time mainly due to advancing therapeutic strategiesA-51-year-old male with a history of well-controlled diabetes mellitus treated with insulin presented to the policlinic of hematology-medical oncology with worsening right inguinal lymphadenopathy for >3 months. He had no complaints of prolonged fever, night sweat, or weight loss. Initial physical examination revealed a healthy male with bulky right inguinal lymphadenopathy. The patient was then referred to a surgeon, and excisional biopsy of the enlarged right inguinal lymph nodes was performed. Therefore, stage II bulky symptomatic low-grade FL was established. We administered chemoimmunotherapy with rituximab and bendamustine every 3 weeks for six cycles. The patient tolerated the treatment well and completed six cycles of chemoimmunotherapy, and the follow-up FDG PET/CT showed complete remission of the disease.The patient achieved complete remission after series of chemoimmunotherapy with Bendamustine-Rituximab. Future assessment is still required for this patient to ensure the remission status of the lymphoma.